Full Text View
Tabular View
No Study Results Posted
Related Studies
Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group
This study has been completed.
Study NCT00836654   Information provided by Fresenius Biotech GmbH

First Received on February 3, 2009.   Last Updated on February 4, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Malignant Ascites
Additional conditions recognized in this trial
Ascites
More general conditions related to this trial
Pathologic Processes
Interventions listed in this trial
Catumaxomab (Removab)
paracentesis
Additional drug interventions recognized in this trial
Antibodies, Bispecific
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Fresenius Biotech GmbH


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services